Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy | Proceedings of the National Academy of Sciences thumbnail
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy | Proceedings of the National Academy of Sciences
www.pnas.org
human MSCs in a highly malignant and invasive model of glioblastoma. MSCs are resistant to the cytokine tumor necrosis factor apoptosis ligand (TRAIL) and, when engineered to express secreted recombinant TRAIL, induce caspase-mediated apoptosis in established glioma cell lines as well as CD133-posit
1 Users
0 Comments
8 Highlights
0 Notes

Top Highlights

  • human MSCs in a highly malignant and invasive model of glioblastoma.
  • MSCs are resistant to the cytokine tumor necrosis factor apoptosis ligand (TRAIL) and, when engineered to express secreted recombinant TRAIL, induce caspase-mediated apoptosis in established glioma cell lines as well as CD133-positive primary glioma cells in vitro
  • engineered MSCs have been shown to exert potent inhibition of tumor growth in an in vivo glioma model and also exhibit a protective effect for the normal brain
  • engineered lentiviral vectors bearing fluorescent and bioluminescent markers to stably label stem cells and tumor cells to study their fate in real time in vitro and in vivo
  • reduced proliferation rate compared with non-transduced cells over several passages in culture

Ready to highlight and find good content?

Glasp is a social web highlighter that people can highlight and organize quotes and thoughts from the web, and access other like-minded people’s learning.